Performance differences among commercially available antigen rapid tests for COVID-19 in Brazil

Página do item simplificado
dc.creatorMariana Lourenço Freire
dc.creatorDaniel Moreira Avelar
dc.creatorGlaucia Fernandes Cota
dc.creatorLindicy Leidicy Alves
dc.creatorCarolina Senra de Souza
dc.creatorJuliana Wilke Saliba
dc.creatorVerônica Faria
dc.creatorMariana Junqueira Pedras
dc.creatorNara de Oliveira Carvalho
dc.creatorGláucia Queiroz Andrade
dc.creatorAna Rabello
dc.date.accessioned2023-12-07T22:51:50Z
dc.date.accessioned2025-09-08T23:36:24Z
dc.date.available2023-12-07T22:51:50Z
dc.date.issued2022-06-16
dc.description.sponsorshipCAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
dc.description.sponsorshipOutra Agência
dc.format.mimetypepdf
dc.identifier.doihttps://doi.org/10.1371/journal. pone.0269997
dc.identifier.issn1932-6203
dc.identifier.urihttps://hdl.handle.net/1843/61859
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofPlos One
dc.rightsAcesso Aberto
dc.subjectTestes de Diagnóstico Rápido
dc.subjectTeste para COVID-19
dc.subjectBrasil
dc.subject.otherAntigen rapid tests
dc.subject.otherCOVID-19
dc.subject.otherBrazil
dc.titlePerformance differences among commercially available antigen rapid tests for COVID-19 in Brazil
dc.typeArtigo de periódico
local.citation.epage13
local.citation.issue6
local.citation.spage1
local.citation.volume17
local.description.resumoA rapid and accurate diagnosis is a crucial strategy for containing the coronavirus disease (COVID-19) pandemic. Considering the obstacles to upscaling the use of RT–qPCR, rapid tests based on antigen detection (Ag-RDT) have become an alternative to enhance mass testing, reducing the time for a prompt diagnosis and virus spreading. However, the performances of several commercially available Ag-RDTs have not yet been evaluated in several countries. Here, we evaluate the performance of eight Ag-RDTs available in Brazil to diagnose COVID-19. Patients admitted to tertiary hospitals with moderate or mild COVID-19 symptoms and presenting risk factors for severe disease were included. The tests were performed using a masked protocol, strictly following the manufacturer’s recommendations and were compared with RT–qPCR. The overall sensitivity of the tests ranged from 9.8 to 81.1%, and specificity greater than 83% was observed for all the evaluated tests. Overall, slight or fair agreement was observed between Ag-RDTs and RT–PCR, except for the Ag-RDT COVID-19 (Acro Biotech), in which moderate agreement was observed. Lower sensitivity of Ag-RDTs was observed for patients with cycle threshold > 25, indicating that the sensitivity was directly affected by viral load, whereas the effect of the disease duration was unclear. Despite the lower sensitivity of Ag-RDTs compared with RT–qPCR, its easy fulfillment and promptness still justify its use, even at hospital admission. However, the main advantage of Ag-RDTs seems to be the possibility of increasing access to the diagnosis of COVID-19 in patients with a high viral load, allowing immediate clinical management and reduction of infectivity and community transmission.
local.identifier.orcidhttps://orcid.org/0000-0003-0538-7403
local.publisher.countryBrasil
local.publisher.departmentHCL - HOSPITAL DAS CLINICAS
local.publisher.departmentMEDICINA - FACULDADE DE MEDICINA
local.publisher.initialsUFMG
local.url.externahttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0269997

Arquivos

Pacote original

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
Performance differences among commercially available antigen rapid tests for COVID-19 in Brazil.pdf
Tamanho:
5.51 MB
Formato:
Adobe Portable Document Format
Baixar

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG